ATE238809T1 - Impfstoffe mit einem ltb adjuvans - Google Patents

Impfstoffe mit einem ltb adjuvans

Info

Publication number
ATE238809T1
ATE238809T1 AT98963503T AT98963503T ATE238809T1 AT E238809 T1 ATE238809 T1 AT E238809T1 AT 98963503 T AT98963503 T AT 98963503T AT 98963503 T AT98963503 T AT 98963503T AT E238809 T1 ATE238809 T1 AT E238809T1
Authority
AT
Austria
Prior art keywords
vaccines
immunogen
vaccine
ltb
adjuvant
Prior art date
Application number
AT98963503T
Other languages
English (en)
Inventor
Etienne Agsteribbe
Rudi Brands
Haan Lolke De
Scharrenburg Gustaaf Johan Van
Willem Ronald Verweij
Jan Christiaan Wilschut
Original Assignee
Duphar Int Res
Universiteit Van Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res, Universiteit Van Groningen filed Critical Duphar Int Res
Application granted granted Critical
Publication of ATE238809T1 publication Critical patent/ATE238809T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT98963503T 1997-11-25 1998-11-24 Impfstoffe mit einem ltb adjuvans ATE238809T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203671A EP0919243A1 (de) 1997-11-25 1997-11-25 Impfstoff, dessen Adjuvant aus B-Untereinheiten des hitzelabilen Enterotoxins (LTB) von Escherichiacoli besteht
PCT/EP1998/007553 WO1999026654A1 (en) 1997-11-25 1998-11-24 Vaccines with an ltb adjuvant

Publications (1)

Publication Number Publication Date
ATE238809T1 true ATE238809T1 (de) 2003-05-15

Family

ID=8228966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963503T ATE238809T1 (de) 1997-11-25 1998-11-24 Impfstoffe mit einem ltb adjuvans

Country Status (25)

Country Link
US (1) US6793928B1 (de)
EP (2) EP0919243A1 (de)
JP (1) JP4235359B2 (de)
KR (1) KR100575019B1 (de)
CN (1) CN1227032C (de)
AT (1) ATE238809T1 (de)
AU (1) AU747061C (de)
BR (1) BR9815413A (de)
CA (1) CA2311492C (de)
CZ (1) CZ299770B6 (de)
DE (1) DE69814177T2 (de)
DK (1) DK1071456T3 (de)
ES (1) ES2198089T3 (de)
HK (1) HK1031102A1 (de)
HU (1) HU226214B1 (de)
IL (2) IL135905A0 (de)
NO (1) NO324690B1 (de)
NZ (1) NZ504396A (de)
PL (1) PL190925B1 (de)
PT (1) PT1071456E (de)
RU (1) RU2211050C2 (de)
SK (1) SK284572B6 (de)
TR (1) TR200001485T2 (de)
UA (1) UA72199C2 (de)
WO (1) WO1999026654A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
AU2003261492B2 (en) * 1998-05-08 2006-09-07 Trident Pharmaceuticals, Inc. Vaccine
EP1075274A2 (de) * 1998-05-08 2001-02-14 University Of Bristol Immunomodulatoren für impstoffen
JP4889175B2 (ja) * 1999-10-18 2012-03-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 感染性因子に対する免疫応答を刺激するための組成物および方法
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
US20060002960A1 (en) * 2003-12-09 2006-01-05 Paul Zoeteweij GM1 binding deficient exotoxins for use as immunoadjuvants
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
ES2376010T3 (es) 2006-10-12 2012-03-08 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Prote�?na de fusión de transcriptasa inversa de la telomerasa, nucleótidos que la codifican y usos de la misma.
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
RU2468034C2 (ru) 2007-08-27 2012-11-27 ЛОНГХОРН ВЭКСИНС ЭНД ДИАГНОСТИКС ЭлЭлСи Иммуногенные композиции и способы
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2861667C (en) 2007-10-01 2017-06-13 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and methods of use
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
KR101887040B1 (ko) * 2012-06-20 2018-08-09 고쿠리츠다이가쿠호징 도쿄다이가쿠 점막 면역 부활화제 및 hpv 감염증 치료용 경구 의약 조성물
WO2015089707A1 (zh) 2013-12-16 2015-06-25 财团法人农业科技研究所 生产不耐热肠毒素b亚单位的质粒、方法及其套组
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
EP3704233A4 (de) * 2017-11-01 2021-08-04 Merck Sharp & Dohme Corp. Stabile formulierungen des cytomegalovirus
WO2019139891A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
TWI811673B (zh) * 2020-05-08 2023-08-11 昱厚生技股份有限公司 使用免疫調節劑及包含其之疫苗組合物預防或治療冠狀病毒感染之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (de) 1974-01-14 1977-07-15 Sandoz Ag
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
AU4754490A (en) * 1988-12-07 1990-06-26 University Of Leicester Heat-labile toxin b subunit fusion proteins
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB

Also Published As

Publication number Publication date
HUP0100058A1 (hu) 2001-05-28
RU2211050C2 (ru) 2003-08-27
US6793928B1 (en) 2004-09-21
PT1071456E (pt) 2003-09-30
KR20010032425A (ko) 2001-04-16
EP0919243A1 (de) 1999-06-02
IL135905A0 (en) 2001-05-20
CA2311492C (en) 2011-10-18
AU1875099A (en) 1999-06-15
PL190925B1 (pl) 2006-02-28
BR9815413A (pt) 2000-10-17
AU747061B2 (en) 2002-05-09
EP1071456A1 (de) 2001-01-31
DK1071456T3 (da) 2003-06-02
JP4235359B2 (ja) 2009-03-11
NZ504396A (en) 2002-09-27
PL340635A1 (en) 2001-02-12
HK1031102A1 (en) 2001-06-01
SK284572B6 (sk) 2005-06-02
NO20002613L (no) 2000-05-22
TR200001485T2 (tr) 2001-12-21
KR100575019B1 (ko) 2006-05-02
HUP0100058A3 (en) 2003-03-28
HU226214B1 (en) 2008-06-30
EP1071456B1 (de) 2003-05-02
CZ299770B6 (cs) 2008-11-19
CA2311492A1 (en) 1999-06-03
NO324690B1 (no) 2007-12-03
CN1227032C (zh) 2005-11-16
IL135905A (en) 2006-08-01
SK7762000A3 (en) 2000-11-07
WO1999026654A1 (en) 1999-06-03
CN1280504A (zh) 2001-01-17
NO20002613D0 (no) 2000-05-22
JP2001523729A (ja) 2001-11-27
DE69814177D1 (de) 2003-06-05
DE69814177T2 (de) 2004-04-08
UA72199C2 (en) 2005-02-15
ES2198089T3 (es) 2004-01-16
AU747061C (en) 2005-02-24
CZ20001895A3 (cs) 2000-10-11

Similar Documents

Publication Publication Date Title
DE69814177D1 (de) Impfstoffe mit einem ltb adjuvans
FI943171A (fi) Ureaasipohjainen rokote Helicobacter-infektiota vastaan
HUP9901901A2 (hu) Hepatitis C elleni vakcinák
DK0573614T3 (da) Svækket, genteknologisk fremstillet pseudorabiesvirus S-PRV-155 samt anvendelse heraf
FI953608A (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella
RU93058676A (ru) Оральное лечение геликобактерной инфекции
CA2201598A1 (en) Vaccine compositions
DE69327553D1 (de) E.Coli P-Fimbriae als immunogener Träger gegen GnRH
ATE261314T1 (de) P53 impfstoff
HU9202976D0 (en) Vaccine acting against anaemy of chicken
WO1999065518A3 (en) Lt and ct in parenteral immunization methods against helicobacter infection
ATE392429T1 (de) Lebend-impfstoff gegen heliobacter pylori
WO2000074630A3 (en) Dna vaccine for protecting an avian against infectious bursal disease virus
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
DK0729509T3 (da) Vaccine imod fåresyge indeholdende en Jeryl-Lynn virus-stamme
ATE195427T1 (de) Pertussistoxin enthaltender influenzaimpfstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1071456

Country of ref document: EP

EEIH Change in the person of patent owner